Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methylphenidate HCl: therapy for attention deficit hyperactivity disorder.

Philip K Capp1, Phillip L Pearl, Charles Conlon

  • 1George Washington University, Department of Neurology, Children's National Medical Center, School of Medicine, Washington DC, USA.

Expert Review of Neurotherapeutics
|June 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postnatal gene restoration in succinic semialdehyde dehydrogenase deficiency (SSADHD) reveals phenotype reversibility.

bioRxiv : the preprint server for biology·2026
Same author

Comparison of Myeloarchitectonic Feature Recognition of the Primary Visual Cortex at 7 T Relative to 3 T MRI.

Journal of magnetic resonance imaging : JMRI·2026
Same author

Predicting surgical outcome in drug-resistant epilepsy by combining interictal biomarkers within a machine learning framework.

Scientific reports·2026
Same author

A patient with a rare metabolic disease and myo-inositol administration leading to a new treatment for epilepsy.

Molecular genetics and metabolism·2026
Same author

International Consensus on the Evaluation and Management of Hypothalamic Hamartomas: Results From a Modified Delphi Survey.

Neurology·2026
Same author

Pediatric frontal lobe epilepsy surgery: long-term neuropsychological outcomes and their predictors.

Epilepsy & behavior : E&B·2026

Methylphenidate is a key treatment for attention deficit hyperactivity disorder (ADHD). While effective in various forms, its mechanism involves dopamine and norepinephrine, with combined therapy showing promise.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Child Psychiatry

Background:

  • Attention deficit hyperactivity disorder (ADHD) is a common childhood neuropsychiatric disorder.
  • Methylphenidate is a primary pharmacological treatment for ADHD.

Purpose of the Study:

  • To review the efficacy, tolerability, and mechanism of action of methylphenidate.
  • To discuss different methylphenidate formulations and their impact on kinetics.
  • To highlight the benefits of combined medication and behavioral therapy for ADHD.

Main Methods:

  • Literature review of methylphenidate's pharmacological properties.
  • Analysis of clinical studies on methylphenidate efficacy and adverse effects.
  • Examination of data from the National Institutes of Health-sponsored multimodal treatment study of ADHD.

Related Experiment Videos

Main Results:

  • Methylphenidate, particularly the D-threo-isomer, is effective for ADHD in children and adults.
  • Various formulations exist with differing kinetics but no clear group-level advantage in efficacy or tolerability.
  • Common side effects include insomnia and appetite disturbance.
  • The drug primarily increases synaptic dopamine by inhibiting the dopamine transporter (DAT1).

Conclusions:

  • Methylphenidate is a proven ADHD treatment with established efficacy in both immediate- and sustained-release forms.
  • Understanding its mechanism, involving dopamine and norepinephrine, is crucial.
  • A combined medication and behavioral therapy approach is supported by research for optimal ADHD management.